US Oncology Reports First Quarter 20...(2097 750 Acquisition of pro...),Health

Acquisition of property and equipment (23,624) (17,427)

Designation of restricted cash (500) -

Investment in unconsolidated subsidiaries 171 -

Payments made in practice affiliation transactions (36,071) -

Distributions from minority interests 511 -

Net cash used in investing activities (57,416) (16,677)

Cash flows from financing activities:

Proceeds from senior floating rate PIK toggle notes,

net of issue costs - 413,300

Proceeds from other indebtedness - 665

Repayment of senior floating rate notes - (256,766)

Repayment of term loan (1,232) (3,791)

Repayment of other indebtedness (341) (369)

Payment of dividends on preferred stock - (25,000)

Payment of dividends on common stock - (323,580)

Debt financing costs (16) -

Distributions to minority interests (768) (994)

Proceeds from exercise of options 25 517

Net cash used in financing activities (2,332) (196,018)

Decrease in cash and equivalents (8,868) (188,965)

Cash and equivalents:

Beginning of period 149,257 281,768

End of period $140,389 $92,803